Workflow
BHGB(833575)
icon
Search documents
康乐卫士(833575) - 第五届董事会第十次会议决议公告
2025-06-11 13:15
证券代码:833575 证券简称:康乐卫士 公告编号:2025-075 北京康乐卫士生物技术股份有限公司 第五届董事会第十次会议决议公告 4.发出董事会会议通知的时间和方式:2025 年 6 月 6 日以邮件和电话方式发 出 5.会议主持人:董事长刘永江先生 6.会议列席人员:部分监事、高级管理人员 7.召开情况合法、合规、合章程性说明: 本次会议的召集、召开、议案审议程序符合相关法律、行政法规、部门规章、 规范性文件和《公司章程》等有关规定。 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 (一)会议召开情况 1.会议召开时间:2025 年 6 月 10 日 2.会议召开地点:公司会议室 3.会议召开方式:现场与通讯相结合的方式 3.回避表决情况: 该议案涉及关联交易事项,根据《北京证券交易所股票上市规则》7.2.11 相 关规定,本议案无需回避表决。 4.提交股东会表决情况: (二)会议出席情况 会议应出席董事 9 人,出席和授权出席董事 9 人。 二、议案审议情况 (一)审 ...
康乐卫士: 股票解除限售公告
Zheng Quan Zhi Xing· 2025-06-05 13:47
Core Viewpoint - The announcement details the lifting of trading restrictions on a total of 38,758 shares of Beijing Kang Le Wei Shi Biotechnology Co., Ltd., which represents 0.01% of the company's total share capital, effective from June 10, 2025 [1]. Summary by Sections Stock Release Details - The total number of shares released from trading restrictions is 38,758, accounting for 0.01% of the company's total share capital [1]. - The trading release is scheduled for June 10, 2025 [1]. Reasons for Stock Release - The reasons for the release of trading restrictions include annual releases for directors, supervisors, and senior management, as well as potential voluntary releases and other specific circumstances [2]. Post-Release Share Capital Situation - After the release, the total share capital of the company will be 280,940,000 shares, with 187,938,680 shares (66.90%) being unrestricted and 93,001,320 shares (33.10%) being restricted [2]. - There are no restricted shares from the company's shareholders that have not fulfilled their commitments [3]. Other Situations - There are no non-operational fund occupation issues related to the shareholders applying for the release of restrictions [2]. - The company has not engaged in any actions that would harm the interests of shareholders applying for the release of restrictions [2].
康乐卫士(833575) - 股票解除限售公告
2025-06-05 13:18
证券代码:833575 证券简称:康乐卫士 公告编号:2025-074 北京康乐卫士生物技术股份有限公司 股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 38,758 股,占公司总股本 0.01%,可交易时 间为 2025 年 6 月 10 日。 二、本次股票解除限售的明细情况及原因 单位:股 | | | 是否为控 股股东、 | 董事、监事、 | 本次解 | 本次解除 | 本次解 除限售 | 尚未解除 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东姓名 | | | | | 股数占 | | | 序号 | | 实际控制 | 高级管理人 | 限售原 | 限售登记 | | 限售的股 | | | 或名称 | 人或其一 | 员任职情况 | 因 | 股票数量 | 公司总 | 票数量 | | | | 致行动人 | | | | 股本比 | | | | | | | | | 例 | | | 1 | 沈益国 ...
北交所策略周报:北证50成份调整公布,同惠电子、一诺威等调入-20250602
Group 1 - The North Exchange 50 Index increased by 2.82% this week, but trading volume significantly decreased, with an average daily trading volume of 25.44 billion yuan, down 29.23% week-on-week [6][11][19] - Market focus shifted from new consumption to the broader technology sector, with strong performances in innovative pharmaceuticals (Nuo Si Lan De +27.37%) and autonomous driving (Xin An Jie +15.17%, Tong Li Co. +11.27%, Hao Miao Technology +11.10%) [6][11][19] - The North Exchange 50 constituent stock adjustment announcement was released, with Tong Hui Electronics and Yi Nuo Wei added to the index, effective June 16 [6][11][12] Group 2 - The North Exchange 50 index closed at 1408.68 points, reflecting a 2.82% increase [20] - The average PE (TTM) for the North Exchange is 88.80 times, with a median of 50.97 times; the average PE for the ChiNext is 75.13 times, with a median of 34.77 times [25][31] - The trading volume for the North Exchange was 6.347 billion shares this week, a decrease of 24.31% week-on-week, with a total trading value of 127.199 billion yuan, down 29.23% [26][29] Group 3 - This week, there were no new IPOs on the North Exchange; as of May 30, 2025, there are 266 companies listed [33] - The North Exchange saw 10 new companies listed and 3 delisted this week, with a total of 6083 companies on the New Third Board [50][51] - The North Exchange's financing balance was 5.538 billion yuan, an increase of 0.08 billion yuan from the previous week [29]
康乐卫士(833575) - 中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司2024年年度持续督导跟踪报告
2025-05-21 13:04
2024 年年度持续督导跟踪报告 | 上市公司 | 北京康乐卫士生物技术股份有限公司 | | --- | --- | | 保荐机构 | 中信证券股份有限公司 | | 保荐代表人 | 赵洞天、王天祺 | | 联系方式 | 010-67805055 | | 联系地址 | 北京市北京经济技术开发区荣昌东街 号 幢 7 A2 201、202 | 中信证券股份有限公司 关于北京康乐卫士生物技术股份有限公司 根据《证券法》《证券发行上市保荐业务管理办法》《北京证券交易所股票 上市规则》和《北京证券交易所证券发行上市保荐业务管理细则》等有关法律、 法规的规定,中信证券股份有限公司(以下简称"中信证券"或"保荐机构") 作为北京康乐卫士生物技术股份有限公司(以下简称"康乐卫士""上市公司" "公司")的持续督导保荐机构,对康乐卫士进行持续督导,现就 2024 年度持 续督导工作总结如下: | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度, | 保荐机构已建立健全并有效执行了持续 | | 1 | 并针对具体的持续督导工作制定相应的 | 督导制度,并根据 ...
康乐卫士(833575) - 北京观韬律师事务所关于北京康乐卫士生物技术股份有限公司2024年年度股东会的法律意见书
2025-05-21 13:01
北京观韬律师事务所 关于北京康乐卫士生物技术股份有限公司 2024年年度股东会的 法律意见书 观意字〔2025〕第 001123 号 致:北京康乐卫士生物技术股份有限公司 北京观韬律师事务所(以下简称"本所")受北京康乐卫士生物技术股份有限 公司(以下简称"公司")之委托,指派本所律师出席公司2024年年度股东会(以 下简称"本次股东会"),并依据《中华人民共和国公司法》(以下简称"《公司法》") 《中华人民共和国证券法》(以下简称"《证券法》")《上市公司股东会规则》(以 下简称"《股东会规则》")以及公司现行有效的《公司章程》的有关规定,出具 本法律意见书。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则(试行)》等规定及本法律意见书出具日 以前已经发生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信 用原则,进行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完 整,所发表的结论性意见合法、准确,不存在虚假记载、误导性陈述或者重大遗 漏,并承担相应法律责任。 本法律意见书中,本所律师仅对本次股东会的召集、召开程序、出席会议人 员资 ...
康乐卫士(833575) - 2024年年度股东会决议公告
2025-05-21 13:01
证券代码:833575 证券简称:康乐卫士 公告编号:2025-071 (一)会议召开情况 1.会议召开时间:2025 年 5 月 20 日 2.会议召开地点:北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 公司会议室 3.会议召开方式:现场与网络投票相结合的方式 4.会议召集人:董事会 5.会议主持人:董事长刘永江先生 北京康乐卫士生物技术股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 6.召开情况合法合规的说明: 本次会议的召集、召开、议案审议程序符合《公司法》等有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 (二)会议出席情况 出席和授权出席本次股东会的股东共 11 人,持有表决权的股份总数 91,199,479 股,占公司有表决权股份总数的 32.46%。 其中通过网络投票参与本次股东会的股东共 3 人,持有表决权的股份总数 101,118 股,占公司有表决权股份总数的 0.04%。 ...
北交所周观察第二十六期:北交所修订重组相关规则,关注北证50成份调整带来的个股变动
Hua Yuan Zheng Quan· 2025-05-18 09:13
Group 1 - The report highlights the second adjustment of the North Exchange 50 Index in 2025, effective on June 16, 2025, with potential new additions including Lierda, Tongguan Mining Construction, Wanda Bearings, Juxing Technology, and Yinuowei [4][10][12] - The report discusses the revision of restructuring rules by the North Exchange, introducing a "small-scale fast" review mechanism and simplified review procedures, aimed at enhancing the efficiency of mergers and acquisitions for innovative SMEs [7][8][9] - The overall PE ratio of North Exchange A-shares has rebounded to 51X, with average daily trading volume increasing to 349 billion yuan, indicating improved market sentiment [17][20] Group 2 - The report suggests that institutional investors in the North Exchange market should adopt a cautious approach, focusing on long-term stable growth companies and sectors aligned with national policies such as "self-control" and innovation-driven development [14] - Key sectors to watch include high-end manufacturing, infrastructure with high dividends, and specialty consumer industries, as well as recent hot themes like AI and robotics [14] - The report notes that the North Exchange 50 Index has increased by 3.13% this week, outperforming other indices, with a year-to-date increase of 37% [22][24]
康乐卫士(833575) - 投资者关系活动记录表
2025-05-16 11:33
证券代码:833575 证券简称:康乐卫士 公告编号:2025-070 北京康乐卫士生物技术股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 活动时间:2025 年 5 月 15 日 15:00-16:30 活动地点:本次业绩说明会采用网络方式举行,公司在上海证券报·中国证 券网路演中心(https://roadshow.cnstock.com/)召开了 2024 年年度报告业绩说明 会。 参会单位及人员:通过网络方式参加公司本次业绩说明会的投资者 上市公司接待人员: 公司董事长、首席科学官:刘永江先生 公司副董事长、首席资本官:李辉女士 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 公司首席财务官:董微女士 公司董事会秘书:任恩奇先生 公司保荐代表人:赵洞天先生 三、 投资者关系活动主要内容 本次业绩说明会公司就投资者普遍关注的问题进行了沟通与交流,主要问题 及 ...
康乐卫士(833575) - 投资者关系活动记录表
2025-05-16 11:20
Group 1: Investor Relations Activity - The investor relations activity was an earnings briefing held online on May 15, 2025, from 15:00 to 16:30 [3] - Key participants included the Chairman, Chief Scientific Officer, Chief Capital Officer, Chief Financial Officer, and the Board Secretary [3] Group 2: HPV Vaccine Development - The three-valent HPV vaccine was included in the priority review list by the National Medical Products Administration (NMPA) in March 2025, with the application accepted in April 2025 [4][5] - The review period for the three-valent HPV vaccine is shortened from 200 working days to 130 working days due to priority review [4] - The nine-valent HPV vaccine for female indications is currently undergoing phase III clinical trials, with the 42 and 48-month visits ongoing [6] - The nine-valent HPV vaccine for male indications is also in phase III trials, with 18 and 24-month visits currently being conducted [6][10] Group 3: Regulatory and Market Strategy - The company is actively communicating with the NMPA to ensure compliance and expedite the review process for the nine-valent HPV vaccine [8] - The nine-valent HPV vaccine (female indication) is expected to submit its Biologics License Application (BLA) soon, with the timeline being a few months behind the three-valent vaccine [7] - The company has adjusted its strategy in Indonesia from building a manufacturing base to collaborating with local partners for registration and market access [13][14] Group 4: Financial and Funding Strategies - The company plans to address funding shortages through various financing channels, including equity and debt financing, while maintaining high R&D investment [16] - A loan of up to 477 million yuan is being organized by a banking syndicate, with approval completed by the lead bank [19] - The company aims to enhance cash flow management and reduce operational costs to improve financial stability [18][20]